Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | BCL6 | P41182 | 2/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GALR1 | P47211 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836499 | 0.93 | IDH2 (0.43) | IDH2BCL6EHMT2EHMT1AXL | |
| SCHEMBL4832236 | 0.92 | IDH2 (0.43) | IDH2BCL6EHMT2EHMT1AXL | |
| SCHEMBL4829436 | 0.91 | EHMT2 (0.50) | IDH2BCL6EHMT2EHMT1GALR1 | |
| SCHEMBL4836250 | 0.90 | BCL6 (0.46) | IDH2BCL6EHMT2EHMT1AXL | |
| Hydrochloric Acid SCHEMBL5550552 | 0.90 | EHMT2 (0.49) | IDH2BCL6EHMT2EHMT1GALR1 | |
| Bromide SCHEMBL6016985 | 0.90 | EHMT2 (0.49) | IDH2BCL6EHMT2EHMT1GALR1 | |
| Hydrochloric Acid SCHEMBL5550550 | 0.89 | EHMT2 (0.49) | IDH2BCL6EHMT2EHMT1GALR1 | |
| SCHEMBL4838644 | 0.88 | IDH2 (0.40) | IDH2BCL6EHMT2EHMT1AXL | |
| SCHEMBL4836933 | 0.88 | EGFR (0.41) | IDH2BCL6EHMT2EHMT1AXL | |
| SCHEMBL14268326 | 0.88 | IDH2 (0.48) | IDH2BCL6EHMT2EHMT1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | claimed |
| US-7132423-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-11-07 | — | — | US | claimed |
| EP-1560817-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004026844-A9 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS INC (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-11-11 | — | — | US | claimed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | claimed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-31 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-11-16 | — | — | US | disclosed |
| US-7132423-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | IDH2 2587/4885BCL6 2097/4885EHMT2 2905/4885 |
| US-20070122444-A1 | Medical devices employing triazine compounds and compositions thereof | AREG, TGFB1, TGFB2 | IDH2 2895/4885BCL6 2802/4885EHMT2 2566/4885 |
| US-20040224950-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | IDH2 2587/4885BCL6 2097/4885EHMT2 2905/4885 |
| US-20060258641-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | IDH2 2587/4885BCL6 2097/4885EHMT2 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.